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Over 500 human microRNAs have been deemed to meet the criteria for microRNA annotation (Fromm et al., 2015) . However, relatively little is known about the identity of individual microRNAs involved in the regulation of hPXR (Dluzen and Lazarus, 2015) . In a previous study on a panel of 25 human liver samples, the levels of hPXR mRNA expression did not correlate with the levels of hPXR protein expression, suggesting the involvement of a posttranscriptional mechanism(s) in hPXR expression (Takagi et al., 2008) . As determined in a cellbased reporter gene assay, miR-148a was shown to regulate hPXR expression by binding to microRNA recognition elements (MRE) in the 3′-untranslated region (3′-UTR) of hPXR mRNA (Takagi et al., 2008) . In a panel of 24 liver samples from the Chinese Han population, a lack of correlation was demonstrated between miR-148a levels and hPXR translational efficiency, as assessed by the ratio of hPXR protein/hPXR mRNA (Wei et al., 2013) . Similarly, miR-148a levels did not correlate with hPXR mRNA or CYP3A4 mRNA levels in a cohort of 92 liver samples from Caucasians (Rieger et al., 2013) . Other studies have implicated miR-30c-1-3p (Vachirayonstien and Yan, 2016) , miR-34a (Ramamoorthy et al., 2012; Lamba et al., 2014) , and miR-449a (Ramamoorthy et al., 2012) in the regulation of hPXR. Overall, much remains to be investigated to identify individual microRNAs as determinants of the expression and functionality of hPXR.
Given that a single mRNA can be targeted by multiple microRNAs (Kim, 2005) , the present study was performed to identify a novel microRNA as a regulator of hPXR. Therefore, we performed bioinformatics analysis to identify microRNAs with sequence complementary to the 3′-UTR of hPXR mRNA and conducted a series of cell-based assays to determine the effect of a select microRNA on the expression and functionality of hPXR. The experimental approaches involved in silico prediction, cell-based reporter gene assay, mimic and inhibitor of microRNA to modulate microRNA expression, and hPXR and CYP3A4 (a hPXR target gene) expression assays. antibody (TA306308) was purchased from OriGene Technologies (Rockville, MD, U.S.A.). DC™ Protein Assay Kit was purchased from Bio-Rad Laboratories (Mississauga, ON, Canada).
Plasmids. The internal control Renilla reniformis luciferase pGL4.74 [hRluc/TK] plasmid
and the pGL3-promoter vector were purchased from Promega (Madison, WI, U.S.A.). The portion of hPXR mRNA from +1041 to +1064 upstream to the coding sequence was identified as a miR18a-5p MRE using www.microRNA.org, an online bioinformatics tool (Betel et al., 2008) . The predicted MRE of miR-18a-5p (three copies of 5′-GGT-ACC-GAA-GAA-CCA-TTT-ACA-TGC-
ACC-TTA-GAA-GAA-CCA-TTT-ACA-TGC-ACC-TTA-GAA-GAA-CCA-TTT-ACA-TGC-ACC-TTA-
CTC-GAG-3′; hPXR-MRE-18a-5p is underlined and italicized) in the 3′-UTR of hPXR mRNA was amplified and cloned into the pGL3-promoter vector using Kpn1 and Xho1 restriction sites downstream of the luciferase gene. This construct was named pGL3-promoter-hPXR-MRE18a.
Similarly, three copies of the complementary sequence of miR-18a-5p MRE (5′-GGT-ACC-CTT-
CTT-GGT-AAA-TGT-ACG-TGG-AAT-CTT-CTT-GGT-AAA-TGT-ACG-TGG-AAT-CTT-CTT-GGT-
AAA-TGT-ACG-TGG-AAT-CTC-GAG-3′
; complementary sequence of miR-18a-5p is underlined and italicized) was amplified and cloned into the pGL3-promoter vector. This construct was named pGL3-promoter-hPXR-MRE18a-REV. A portion containing perfect matching sequence of the mature miR-18a-5p (5′-GGT-ACC-CTA-TCT-GCA-CTA-GAT-GCA-CCT-TAC-TCG-AG-3′; complementary-18a-5p is underlined and italicized) was amplified and cloned into the pGL3-promoter vector. This construct was named pGL3-promoter-complementary-18a. Each of these constructs was synthesized at GenScript (Piscataway, NJ, U.S.A.).
Cell Culture. LS180 human colorectal adenocarcinoma cells (CL-187) (American Type Culture Collection, Manassas, VA, U.S.A.) were cultured as described previously (Yeung et al., 2008) , except that minimum essential medium (MEM)/EBSS was the culture medium and This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on April 13, 2017 as DOI: 10.1124 at ASPET Journals on November 7, 2017 molpharm.aspetjournals.org Downloaded from MEM/non-essential amino acid (1×) was added. All cell-based assays were conducted in supplemented culture medium containing 10% v/v charcoal-stripped fetal bovine serum.
Transient Transfection and Luciferase Reporter Gene Assays.
A miRNA mimic is a small, chemically modified double-stranded RNA used experimentally to provide over-expression of a miRNA of interest (Schaeffer et al., 2012) , whereas a miRNA inhibitor is a small, chemically modified single stranded RNA molecule designed to bind specifically to and decrease the expression of an endogenous microRNA of interest (Lagana et al., 2014) . The effects of a miR18a-5p mimic and a miR-18a-5p inhibitor on the functionality of the 3′-UTR of hPXR mRNA were investigated in transiently transfected LS180 cells, which were seeded in 24-well plates (Biolite, catalog number: 930186, Thermo Fisher Scientific, Burlington, ON, Canada) at a density of 100,000 cells per well in a volume of 0.5 ml of the culture medium described above. At 24 h postplating, cells were transfected with 50 µl of a master transfection mix containing Lipofectamine® 2000 transfection reagent (1.5 µl/well), serum-free Opti-MEM (44.5 µl/well), pGL4.74 [hRluc/TK] (internal control; 10 ng/well), a construct containing the pGL3-promoter backbone (200 ng/well), and either miR-18a-5p mimic (50 nM) or miR-18a-5p inhibitor (50 nM) for 48 h, according to the manufacturer's protocol. Control cells were transfected with the same concentration (50 nM) of a mimic control or an inhibitor control. The pGL3-promoter-containing construct was: 1) pGL3-promoter-hPXR-MRE18a, 2) pGL3-promoter-hPXR-MRE18a-REV, 3) pGL3-promotercomplementary-18a, or 4) the control empty vector (pGL3-promoter). Firefly luciferase and Renilla reniformis (internal control) luciferase activities were quantified and normalized (Sharma et al., 2013) .
Transfection and Drug Treatment of LS180 Cells for Determination of microRNA and mRNA Expression. LS180 cells were seeded in 100 mm culture dishes (Corning Inc., NY, This article has not been copyedited and formatted. The final version may differ from this version. Determination of hPXR and CYP3A4 mRNA Expression. Total RNA was reverse transcribed and total cDNA concentrations were quantified (Sharma et al., 2013) . hPXR cDNA, CYP3A4 cDNA, HPRT cDNA, and cyclophilin cDNA were amplified using gene-specific primers (Lau et al., 2011; Sharma et al., 2015) 
.). Background luminescence was measured in wells devoid of cells but contained the
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Prediction of miR-18a-5p MRE in the 3′-UTR of hPXR mRNA. As shown in Supplemental Table S1 , miR-18a-5p was the top candidate microRNA regulator of hPXR, as predicted by three of the most commonly used bioinformatics tools in microRNA analysis:
TargetScan, miRanda, and DIANA-microT-CDS (Riffo-Campos et al., 2016) . The predicted MRE of miR-18a-5p in the 3′-UTR of hPXR mRNA ranged from position 1041 to 1064 upstream of the coding sequence (Fig. 1) . This information about the MRE was utilized in designing various reporter plasmids to investigate the potential involvement of miR-18a-5p in regulation of the 3′-UTR of hPXR mRNA.
The miR-18a-5p MicroRNA Targeted the 3′-UTR of hPXR mRNA in LS180 Cells.
Plasmids were cloned into the pGL3-promoter vector downstream of the luciferase gene ( Fig. 2A ).
As shown in Fig. 2B , the luciferase activity was less in cultured LS180 cells co-transfected with a miR-18a-5p mimic and pGL3-promoter-hPXR-MRE-18a than the luciferase activity in cells cotransfected with a miR-18-5p mimic and pGL3-promoter (empty vector control) or in cells cotransfected with a mimic control and pGL3-promoter-hPXR-MRE-18a (construct containing 3 copies of miR-18a-5p MRE). There was a further decrease in luciferase activity in cells cotransfected with a miR-18a-5p mimic and pGL3-promoter-complementary-18a (construct with perfect matching complement of miR-18a-5p). As expected, the miR-18a-5p mimic did not influence the luciferase activity in cells transfected with pGL3-promoter-hPXR-MRE-18a-REV (construct containing 3 copies complementary sequence of miR-18a MRE). As shown in Fig. 2C , the luciferase activity was greater in cultured LS180 cells co-transfected with a miR-18a-5p
inhibitor and pGL3-promoter-hPXR-MRE-18a than the luciferase activity in cells co-transfected with a miR-18-5p mimic and pGL3-promoter or in cells co-transfected with a mimic control and This article has not been copyedited and formatted. The final version may differ from this version. pGL3-promoter-hPXR-MRE-18a. There was a further increase in luciferase activity in cells cotransfected with a miR-18a-5p mimic and pGL3-promoter-complementary-18a. As expected, the miR-18a-5p inhibitor did not influence the luciferase activity in cells transfected with pGL3-promoter-hPXR-MRE-18a-REV. Collectively, the results from the complementary experiments involving miR-18-5p mimic (Fig. 2B ) and miR-18a-5p inhibitor (Fig. 2C) showed that the miR18a-5p MRE in the 3′-UTR of hPXR mRNA was functional.
Expression Profile of miR-18a-5p in LS180 Cells Transfected with a Mimic or
Inhibitor of miR-18a-5p. Initial experiments confirmed that transfection reagent, mimic control, and treatment with either rilpivirine or rifampin did not alter miR-16-5p level (data not shown).
Therefore, the level of miR-18a-5p was normalized to that of miR-16-5p. Transfection of LS180 cells with a miR-18a-5p mimic (25 nM) led to an increase in miR-18a-5p expression, as assessed at 24 h post-transfection. Prolonging the duration of transfection to 48 and 72 h decreased the measured level of miR-18a-5p, in comparison to the measured miR-18a-5p level at 24 h (Fig. 3A) .
As shown in Fig. 3B , the increase in miR-18a-5p expression was comparable in cells transfected with either 25 or 50 nM of the miR-18a-5p mimic for 48 h (Fig. 3B) . By comparison, transfection of LS180 cells with the miR-18a-5p inhibitor (25 nM) decreased the measured level of miR-18a-5p
at 24, 48, and 72 h post-transfection (Fig. 3C ). Similar decreases in the level of miR-18a-5p were obtained with either 25 or 50 nM of the miR-18a-5p inhibitor (Fig. 3D ). Based on these results, 48
h transfection period and 50 nM concentration of the miR-18a-5p mimic or inhibitor were used in subsequent experiments.
A miR-18a-5p Mimic and a miR-18a-5p Inhibitor Reciprocally Modulated hPXR Expression in LS180 Cells. The effects of a miR-18a-5p mimic and a miR-18a-5p inhibitor on hPXR expression were investigated. Transfecting LS180 cells with a miR-18a-5p mimic at a This article has not been copyedited and formatted. The final version may differ from this version. concentration (25 or 50 nM) that increased the level of miR-18a-5p ( Fig. 3A and 3B ) was associated with a decrease in the level of hPXR mRNA (Fig. 4A ) and protein (Fig. 4B) .
Conversely, transfecting LS180 cells with a miR-18a-5p inhibitor at a concentration (25 or 50 nM)
that decreased the level of miR-18a ( Fig. 3C and 3D ) was associated with an increase in hPXR mRNA (Fig. 4C) and protein (Fig. 4D) change the level of miR-18a-5p over the 24 h period. In the same samples, rifampin and rilpivirine did not modulate hPXR mRNA level over the 24 h time period (Fig. 5B) . Control analysis indicated an increase in CYP3A4 mRNA level by rifampin and rilpivirine. However, a novel aspect of our data is the differential temporal profile. As shown in Fig. 5C , the increase in CYP3A4 mRNA level in LS180 cells by rifampin occurred at 12 and 24 h post-treatment, whereas it was not apparent until after 24 h of rilpivirine treatment. The same conclusion was drawn regardless of whether the PXR mRNA and CYP3A4 mRNA levels were normalized to those of HPRT mRNA ( Fig. 5B and Fig. 5C ) or cyclophilin mRNA (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. Over-expression of miR-18a-5p Compromised Inducibility of a hPXR Target Gene (CYP3A4) in LS180 Cells Treated with a hPXR Agonist. The effect of miR-18a-5p overexpression on hPXR functionality was investigated in LS180 cells transfected with the miR-18a-5p mimic and treated with a hPXR agonist, rifampin or rilpivirine. When compared with cells transfected with a mimic control and treated with rifampin or rilpivirine, the miR-18a-5p mimic attenuated the extent of CYP3A4 induction by either of these drugs, as shown by the reduced level of CYP3A4 mRNA (Fig. 6A ) and CYP3A4 catalytic activity (Fig. 6B) . The same conclusion was drawn regardless of whether the CYP3A4 mRNA level was normalized to that of HPRT mRNA (Fig. 6A ) or cyclophilin mRNA (data not shown).
Discussion
The miR-18a-5p microRNA and the other members in the miR-17/92 cluster (miR-17-5p, miR-17-3p, miR-19a, miR-19b, miR-20a, and miR-92a) are oncogenes shown to be over-expressed in various types of human cancer (Mogilyansky and Rigoutsos, 2013) . In a previous bioinformatics analysis using three alogorithms (TargetScan, microcosm, and miRDB) and a miRNA ranking tool known as MIRNA-DISTILLER (Rieger et al., 2011) , hPXR was predicted to be a target of miR-18a-5p (Rieger et al., 2013) , consistent with the prediction summarized in Supplemental Table S1 . However, prior to our current study, there were no published experimental data to indicate whether miR-18a-5p had any functional interaction with key regulators (e.g., hPXR) of genes involved in drug transport or biotransformation.
A major conclusion of our study is that miR-18a-5p is a post-transcriptional regulator of hPXR. This conclusion is supported by: 1) bioinformatics analysis of the 3′-UTR of hPXR mRNA identified a MRE for miR-18a-5p; 2) miR-18a-5p MRE in the 3′-UTR of hPXR mRNA was functional in a cell-based reporter gene assay; and 3) modulation of miR-18a-5p expression by a mimic or inhibitor altered hPXR expression in LS180 cells. It is possible that miR-18a-5p crosstalks with glucocorticoid receptor in mediating its modulatory effect on hPXR, based on the finding that miR-18a-5p regulates the expression of glucocorticoid receptor (Vreugdenhil et al., 2009 ) shown previously to influence hPXR expression (Pascussi et al., 2001) . However, LS180 cells do not express glucocorticoid receptor (Maier et al., 2007) , nullifying the possibility of a role of the glucocorticoid receptor in hPXR regulation by miR-18a-5p in this cell line. Overall, our findings indicate that miR-18a-5p regulates hPXR expression by targeting its MRE in the 3′-UTR of hPXR mRNA.
This article has not been copyedited and formatted. The final version may differ from this version. Regulation of hPXR expression by miR-18a-5p is associated with functional consequences, as demonstrated by the finding that over-expression of miR-18a by transfecting LS180 cells with a mimic of miR-18a-5p compromised the inducibility of a hPXR target gene (CYP3A4). Consistent with this conclusion, transfection of LS180 cells with a miR-18a-5p mimic attenuated the increase in CYP3A4 mRNA expression and CYP3A4 catalytic activity by rifampin and rilpivirine, which are hPXR agonists and CYP3A4 inducers (Bertilsson et al., 1998; Lehmann et al., 1998; Sharma et al., 2013) . In contrast, transfection with a mimic of miR-18a-5p did not alter CYP3A4 expression in vehicle-treated control LS180 cells, suggesting a lack of a direct effect of miR-18a-5p on CYP3A4 basal expression. It should be noted that miR-18a-5p has sequence complementarity in the 3′-UTR of hPXR mRNA but not in the 3′-UTR of CYP3A4 mRNA. Furthermore, basal , and hepatocyte nuclear factor-4α (Tegude et al., 2007) . PXR does not appear to play a role in the basal expression of CYP3A because little or no difference exists in hepatic CYP3A mRNA level between untreated wild-type mice and untreated PXR knockout mice (Xie et al., 2000; Helsley et al., 2013) . Overall, miR-18a-5p compromised the functionality of hPXR in LS180 cells by attenuating the inducibility of a hPXR target gene (CYP3A4).
As shown in the present study, transfection of LS180 cells with a miR-18a-5p mimic resulted in ~25-fold increase in miR-18a-5p level and this was accompanied by ~30% decrease in hPXR mRNA level. By comparison, a 25% decrease in miR-18a-5p level in LS180 cells by a miR-18a-5p inhibitor was sufficient to elicit a 55% increase in hPXR mRNA level. Such an apparent difference between a miRNA mimic and a miRNA inhibitor is consistent with previous observations. For example, transfection of HepaRG cells with a miR-25-3p mimic increased miRThis article has not been copyedited and formatted. The final version may differ from this version. 25-3p levels by almost 175-fold, but decreased CYP2B6 mRNA level by only ~40%, whereas transfection with a miR-25-3p inhibitor decreased miR-25-3p level ~75% and this led to a ~25% increase in CYP2B6 mRNA level (Jin et al., 2016) . The low efficiency in which a microRNA mimic decreases the expression of a target has been shown for other combinations of microRNA mimic and target, including miR-148a mimic and hPXR (Takagi et al., 2008) ; miR-103 mimic and CYP2C8 (Zhang et al., 2012) , and miR-130-3p mimic and sphingosine 1-phosphate receptor 2 (Fan et al., 2016) . The underlying reason for the low efficiency of a microRNA mimic is presently not known, but it may relate to the chemical modification to the RNA molecule introduced in the synthesis of a mimic (Sokilde et al., 2015) .
Several psychoactive drugs, including harmaline, which is an indole alkaloid, have been reported to decrease miR-18a-5p expression in cultured SH-SY5Y human neuroblastoma cells (Rodrigues et al., 2011) . In the present study, the hPXR agonists rifampin and rilpivirine decreased the endogenous expression of miR-18a-5p in untransfected LS180 cells, and this occurred in a time-dependent manner and preceded the onset of induction of a hPXR target gene (CYP3A4) by rifampin and rilpivirine. The temporal profile obtained from our time course experiment indicated that the reduction in endogenous miR-18a-5p expression by the drugs was a relatively early event, which was evident at 3 h post-drug treatment. The level of miR-18a-5p returned to baseline level by 12 h after rifampin treatment and by 24 h after rilpivirine treatment.
Consistent with our finding, rifampin did not alter miR-18a-5p level in human hepatocytes when assessed at 48 h post-drug treatment in a microarray experiment (Takahashi et al., 2014) .
Therefore, it is necessary to include early time points in order to detect changes in endogenous expression of a microRNA. While our study is the first to report modulation of microRNA expression by rilpivirine, previous microarray analyses have shown increased and decreased levels This article has not been copyedited and formatted. The final version may differ from this version. of various microRNAs by rifampin in primary cultures of human hepatocytes (Ramamoorthy et al., 2013; Takahashi et al., 2014) . The mechanism of miR-18a-5p suppression by rifampin and rilpivirine is not known, but it may involve perturbation at one or more of the multi-steps involved in microRNA biogenesis, such as transcription, nuclear maturation, export from the nucleus to the cytoplasm, and cytoplasmic processing (Beermann et al., 2016) . Post-transcriptional and epigenetic alterations are also key determinants governing microRNA expression . Future studies will be needed to elucidate the cellular and molecular mechanisms by which drugs and other chemicals modulate microRNA expression.
According to the current study, transfection of LS180 cells with a miR-18a-5p mimic decreased hPXR mRNA and protein expression when assessed at 48 h post-transfection. In contrast, treatment of untransfected LS180 cells with rifampin or rilpivirine did not change hPXR mRNA level at 3, 6, 12, or 24 h after drug treatment, but this was associated with an increase in CYP3A4 mRNA level at 12 and 24 h post-rifampin treatment and at 24 h post-rilpivirine treatment.
Consistent with our data, previous studies have also reported a lack of an effect of rifampin on hPXR mRNA and protein levels when assessed at 24 h post-rifampin treatment in LS174T human colorectal carcinoma cells (Kim et al., 2017) , IHH immortalized human hepatocytes (Berthier et al., 2012) , and primary cultures of human hepatocytes (Ayed-Boussema et al., 2012) . However, prolonging the exposure to rifampin to 72 h is associated with an increase in hPXR expression, as demonstrated in T84 human colorectal carcinoma cells (Haslam et al., 2008) . Therefore, it appears there is a lag time for the increase in hPXR expression to be evident, but a detailed time course study in the same cell culture model will be needed to characterize the temporal pattern. Adding to the intricacy, other cellular factors are likely to be associated with the interaction between microRNAs, nuclear receptors, and their target genes. For example, the down-regulation of miRThis article has not been copyedited and formatted. The final version may differ from this version. 122, activation of CAR, and induction of CAR target gene (CYP2B) by phenobarbital are associated with activation of AMP-activated protein kinase by the drug (Shizu et al., 2012) .
Therefore, studies will be required in the future to provide an understanding of how miR-18a-5p
regulates the expression and functionality of hPXR.
In summary, 1) miR-18a-5p was a post-transcriptional regulator of hPXR, 2) overexpression of miR-18a-5p compromised the functionality of hPXR by attenuating the inducibility of a hPXR target gene (CYP3A4) by rifampin and rilpivirine, and 3) rifampin and rilpivirine decreased the endogenous expression of miR-18a-5p, as determined in the present study performed in LS180 human colon adenocarcinoma cells. Given that PXR is a master regulator of various genes function in drug transports and biotransformation (Chai et al., 2013) , our finding on the interaction between miR-18a-5p and hPXR provides additional insight into the molecular determinants of the inter-individual variability in pharmacokinetics and pharmacodynamics.
Suppression of miR-18a-5p expression by rifampin and rilpivirine may have implication with respect to the proposed utility of miR-18a-5p as a diagnostic biomarker for various types of cancers (Komatsu et al., 2014) because of the potential interference of drug intake on miR-18a-5p
expression. Finally, suppression of miR-18a-5p has been associated with inhibition of cell invasion and promote apoptosis (Zhu et al., 2015) . Therefore, drug-mediated suppression of miR18a-5p may be a target of interest in future investigations on anti-cancer strategies.
This article has not been copyedited and formatted. The final version may differ from this version. the corresponding reporter plasmid and mimic control, and the group co-transfected with the pGL3-promoter (empty vector control) and a miR-18a-5p mimic (P < 0.05). were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Immunoblots were This article has not been copyedited and formatted. The final version may differ from this version. of three independent experiments performed in duplicate. *, significantly different from the corresponding mimic control group (P < 0.05). Methods. Data are expressed as mean ± S.E.M. for three independent experiments performed in triplicate. *, significantly different from the corresponding mimic control group (P < 0.05).
